A significant adverse reaction was noted in one participant of a clinical trial on a COVID-19 vaccine being developed by AstraZeneca in partnership with Oxford University. Details on the serious side effect or the United Kingdom-based study…

As a dentist, operating your dental practice involves so much more than just clinical care. There are many aspects to managing the business that you likely never learned in school. Utilizing dental practice consultants can help lessen the…

ErgoFinger® wearable high-volume evacuation device reduces physical stress as well as aerosol contamination.

Kathleen T. O’Loughlin, DMD, MPH, executive director of the American Dental Association, asked members of a National Academies, Engineering, and Medicine panel—who are working on a plan for the equitable distribution of COVID-19 vaccines—to…

A policy brief from  UCLA Center for Health Policy Research shows low-income California adults are less likely to receive regular dental checkups and more likely to visit the dentist for specific problems than those with higher incomes. 

While the United States has spent more than $10 billion on vaccine development, funds have not been allocated to support public health departments in rolling out two COVID-19 vaccines that may be ready as early as late October or the…

Approximately 69% of COVID-19 infections went undiagnosed among 3,000 frontline healthcare professionals between April and June in 12 states, according to new research published in the United States Morbidity and Mortality Weekly Report.…

A study published in Neurology,  the journal of the American Academy of Neurology, suggests periodontitis may be linked to mild cognitive impairment and dementia later in life, especially when it is severe and results in tooth loss. 

In a letter to the biopharmaceutical industry, CEOs from Ovid Therapeutics, Nkarta Therapeutics, Global Blood Therapeutics, Biotechnology Innovation Organization, Acorda Therapeutics, GlycoMimetics, Alnylam Pharmaceuticals, and Alkermes…

As yet unidentified, Vaccine A and Vaccine B should be ready for national distribution by late October or early November, according to the United States Centers for Disease Control and Prevention (CDC). The vaccines will initially be used…